Uncategorized
OKYO Pharma Announces Potent Anti-inflammatory Effects of OK-113, a Novel Agonist of Chemerin G-Protein Coupled Receptor, in a Mouse Model of Dry Eye Disease
LONDON--(BUSINESS WIRE)--OKYO Pharma Limited (LSE: OKYO) August 28, 2019, a biotechnology company focusing on the G Protein Coupled Receptors (GPCR) targeted drugs for treatment of dry eye disease (DED) and non-opioid analgesic for management of chronic pain, is pleased to announce potent anti-inflammatory activity of OK-113, an in-house discovered proprietary agonist of Chemerin GPCR, in an experimental model of DED in mice. These preclinical efficacy data, identifying a lead drug candidate, w